What it sells
AI-run end-to-end clinical trials.
Business model breakdown
Buyer: who owns the budget?
UnverifiedClinical development, data management, biostatistics, medical writing and regulatory leads at pharma/biotech sponsors, plus R&D heads in materials firms (site routes by role).
Trigger: what makes them buy now?
Trial design takes about 3 months, traditional CROs stack headcount with data silos, and multi-country filing (Japan especially) is complex while competitors race to market.
Workflow: what inputs become what output?
AI CRO 6.0 runs trial protocol design, data capture and QC, statistical analysis and CSR report drafting with AI agents plus human experts, claiming up to 12x faster protocol design and 15x faster medical writing.
Economics: what it saves and how it charges
Service-plus-AI CRO model replacing headcount stacking; claims up to 12x faster protocol design (3 months to 1 week), 15x medical writing, 50x monitoring, 10x data management; says commercial loop closed in 2021 with sustained profitability.
Distribution: how it reaches customers
UnverifiedDirect enterprise sales through contact page, with Chinese, US and Japanese regulatory submission support (3 continents).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2025-12-10 | Series D | nearly $50M | — | m.36kr.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-13.